<DOC>
	<DOC>NCT00124982</DOC>
	<brief_summary>The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.</brief_summary>
	<brief_title>Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Completed doubleblind portion of the IM101064 study. Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis American College of Rheumatology (ACR) functional class I, II, III Subjects currently or previously received an antiTNF therapy at an approved labeled dose for at least 3 months Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules) History of cancer within the last 5 years (other than nonmelanoma skin cell cancers cured by local resection)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>